A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

Exclusion Criteria

• •Prior treatment for metastatic or unresectable disease (Note: prior adjuvant or neo-adjuvant therapy for local disease is allowed if ended more than 6 months of 1st dose).
• •Prior treatment with any selective inhibitor of fibroblast growth factor - fibroblast growth factor receptor (FGF-FGFR) pathway.
• •Known human epidermal growth factor receptor 2 (HER2) positive
• •Untreated or symptomatic central nervous system (CNS) disease or brain metastases.
• •Peripheral sensory neuropathy greater than or equal to Grade 2.
• •Clinically significant cardiac disease.
• •Other malignancy within the last 2 years (exceptions for definitively treated disease).
• •Chronic or systemic ophthalmological disorders.
• •Major surgery or other investigational study within 28 days of first study treatment dose.
• •Palliative radiotherapy within 14 days of first study treatment dose.
• •Abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer.
• •History or evidence of systemic disease or ophthalmological disorders requiring chronic use of ophthalmic corticosteroids.